Vetoquinol’s Q3 2026 Sales Accelerate 10.4% to €140 Mn as Essentials Portfolio Drives Growth

Vetoquinol delivers 10.4% Q3 revenue growth as Essentials portfolio strengthens its position

French veterinary pharmaceutical company Vetoquinol reported a significant acceleration in third-quarter 2026 sales, with revenue reaching €139.7 million, an increase of 10.4% compared with the corresponding quarter of 2025. At constant exchange rates, quarterly growth was 9.6%, reflecting stronger underlying trading performance across most of the company’s strategic territories.

The company’s nine-month revenue reached €399.0 million, up 3.9% on a reported basis and 5.4% at constant exchange rates. Growth was driven principally by its Essentials portfolio, which expanded by 6.7% at constant exchange rates and accounted for 64.9% of group revenue at the end of September.

The results provide an important indication of Vetoquinol’s strategic direction: a greater concentration of commercial resources around established, scalable veterinary products with recurring clinical relevance, supported by geographical expansion and portfolio rationalisation.

For competing animal-health companies, the results offer several important signals about portfolio economics, regional market opportunities and the competitive importance of products that veterinarians use routinely across companion-animal and livestock practices.

Q3 2026 financial performance: sequential acceleration becomes visible

Vetoquinol’s quarterly performance improved progressively during the first nine months of 2026.

Quarterly revenue performance

The progression is commercially significant. After a relatively weak first quarter, Vetoquinol returned to growth in Q2 and delivered a substantially stronger Q3. Revenue increased from €125.0 million in Q1 to €139.7 million in Q3, a sequential increase of approximately 11.8%.

However, sequential revenue movement should not be interpreted as organic market growth because quarterly sales are influenced by seasonality, product mix, commercial timing and geographical exposure.

The company also acknowledged a favourable base effect in Q3, following the previous year’s third-quarter performance.

Essentials portfolio: the most important strategic signal

The strongest feature of Vetoquinol’s Q3 announcement is the performance of its Essentials portfolio. The company reported that Essentials products grew by:

• 13.9% in Q3 on a reported basis.

• 12.9% in Q3 at constant exchange rates.

• 6.0% during the first nine months on a reported basis.

• 6.7% during the first nine months at constant exchange rates.

At the end of September 2026, Essentials generated €259 million in revenue and represented 64.9% of total group sales, compared with 63.6% during the corresponding period of 2025.

Essentials portfolio performance

The 2025 revenue equivalent is approximate, calculated from the reported 2026 value and growth rate.

Vetoquinol defines Essentials as veterinary medicines and non-medicated products that are established leaders or have the potential to become leaders. They address routine requirements of veterinarians in companion-animal and farm-animal practices and are intended for international commercialisation.

This is an important distinction: Essentials is not simply a therapeutic category. It is a portfolio-management strategy built around products with potential for scale, repeat demand and broader geographical deployment.

Why this model matters

A portfolio of established, frequently used veterinary products can offer several commercial advantages:

1. Recurring demand: Products addressing routine veterinary requirements can generate repeat purchasing.

2. Commercial scalability: Established products can be marketed across multiple geographies, subject to local regulatory approvals.

3. Veterinary familiarity: Products with established clinical recognition may benefit from existing prescribing and recommendation habits.

4. Distribution leverage: A focused portfolio can improve the efficiency of sales-force deployment and distribution.

5. Portfolio concentration: Greater revenue contribution from selected products can support commercial focus, although it also increases dependence on their performance.

For competitors, the key strategic question is whether their portfolios contain sufficient high-volume, repeat-use products capable of generating similar scale.

The Essentials performance suggests that Vetoquinol is obtaining meaningful growth from its existing commercial portfolio rather than relying exclusively on new product introductions or acquisitions.

Geographic performance: the United States and Asia-Pacific provide important growth signals

Vetoquinol reported positive growth across most of its strategic territories during the first nine months of 2026. The strongest constant-currency performance came from the United States, followed by Europe and Asia-Pacific/Rest of the World.

Nine-month revenue by strategic territory

Source: Vetoquinol, sales at end September 2026.

United States: strongest major-market growth

The United States recorded 12.4% growth at constant exchange rates, making it the strongest performing major territory during the nine-month period. Revenue increased from €80.3 million to €86.9 million on a reported basis.

The US market remains strategically important for international veterinary pharmaceutical companies because of its large companion-animal healthcare market, developed veterinary distribution infrastructure and significant livestock production base.

For Vetoquinol, the US performance reinforces the importance of its established distribution and product portfolio in a high-value market.

For competitors, the result highlights the importance of commercial execution, product availability and veterinary-channel engagement. However, the announcement does not disclose the individual therapeutic categories or products responsible for the US growth. It would therefore be inappropriate to attribute the increase to a specific brand or disease category.

Europe: stable growth in Vetoquinol’s established market

Europe generated €197.8 million, representing approximately 49.6% of nine-month group revenue. Constant-currency growth was 4.6%.

The region remains Vetoquinol’s largest geographical market, reflecting its established European presence and distribution infrastructure. The moderate growth rate compared with the US suggests that the group’s incremental growth opportunity is increasingly supported by performance outside its traditional European base.

Asia-Pacific and Rest of World: strong underlying performance despite currency effects

The Asia-Pacific/Rest of World territory generated €60.6 million, representing 4.6% growth at constant exchange rates. Reported revenue was marginally lower than in the previous year because of currency effects.

This is an important distinction for market analysts: the reported decline of 0.2% does not reflect the underlying constant-currency growth reported by the company.

Asia-Pacific remains strategically relevant to animal-health manufacturers because of its heterogeneous livestock production systems, expanding companion-animal markets and differing levels of veterinary healthcare penetration.

For competitors, the region offers opportunities in veterinary pharmaceuticals, parasiticides, vaccines, nutritional products, diagnostics and farm-health management.

However, the Vetoquinol announcement does not provide country-level growth or a breakdown between companion-animal and livestock sales within the region.

Americas excluding the United States: an area requiring attention

This territory recorded a 0.9% decline at constant exchange rates, despite a marginally positive reported growth rate. It was the only strategic territory to report a constant-currency decline.

The result suggests that Vetoquinol’s performance was not uniformly positive across all markets. Competitors should monitor whether this reflects market-specific demand, product rationalisation, distribution challenges or other operational factors. The company has not provided sufficient detail to identify the precise cause.

Product-line simplification: deliberate portfolio rationalisation has a measurable revenue impact

Another important component of the announcement is Vetoquinol’s ongoing simplification of complementary product ranges. The company reported:

• A negative €0.6 million impact during Q3 2026.

• A cumulative negative €3.7 million impact during the first nine months of 2026.

• A negative €7.7 million impact during the corresponding nine-month period of 2025.

The company stated that the impact was consistent with the normalisation of its product-line simplification programme.

Company profile: Vetoquinol

Vetoquinol is an independent international animal-health company founded in 1933 and listed on Euronext Paris since 2006 under the ticker VETO.

The company develops and markets veterinary medicines and non-medicated products for companion animals, including dogs and cats, and farm animals, including cattle and pigs. It operates across Europe, the Americas and Asia-Pacific. Vetoquinol reported a workforce of 2,526 employees as of 30 June 2026.

Next scheduled financial publication: Full-year 2026 sales, 14 January 2027, after market close.